超声引导下经皮射频消融治疗黏膜下子宫肌瘤的有效性和安全性

 目的 探讨超声引导下经皮射频消融治疗黏膜下子宫肌瘤的有效性和安全性。方法 回顾性分析2016-03至2017-11收治的78例有症状的黏膜下子宫肌瘤,计算子宫肌瘤的完全消融率并评价治疗结果,比较术后3个月子宫肌瘤体积、血红蛋白(Hb)定量及子宫肌瘤症状及健康相关生活质量问卷(UFS-QOL)评分。观察和记录治疗过程中及治疗后随访期间患者出现的各种不良反应及并发症。结果 射频消融后3、6、9、12个月病灶体积缩小率分别为65.3%、75.6%、81.5%和91.6%。治疗3个月后,体积减少(35.1±9.7)cm³,血红蛋白增加(31.9±44.05 )g/L,UFS-QOL评分中SSS评分减少(24.7±13.2),HRQL评分增加(17.3±18.65),差异均有统计学意义(P＜0.01)。术后3 d检查未发现严重并发症。结论 超声引导下经皮射频消融治疗黏膜下子宫肌瘤是一种安全有效的治疗方法,适合对子宫保留有需求的患者。     

发散式体外冲击波治疗距骨骨软骨损伤的效果

 目的 评价发散式体外冲击波疗法治疗距骨骨软骨损伤的效果。方法 选取2010-01至2016-06武警总医院就诊,并采用发散式冲击波治疗的距骨骨软骨损伤54例60个距骨,治疗方案为能量1.5～2.5 bar,5Hz,冲击2000～3000次,5次为一疗程,共治疗3～4疗程。治疗结束后3、6、12个月进行随访,通过患者踝关节VAS疼痛评分、美国足与踝协会踝与后足评分和MRI矢状面损伤面积大小评价治疗效果。结果 治疗结束后3个月,患者VAS评分降低,AOFAS评分升高,与治疗前比较均有统计学差异(P＜0.05)。治疗结束后6、12个月,患者踝关节疼痛持续缓解,功能评分不断提高(P＜0.01);治疗前平均损伤面积(2.67±1.14)cm²,治疗结束后3个月(1.97±0.77)cm²,6个月(1.04±0.61)cm²和12个月(0.46±0.25)cm²缩小更明显(P＜0.01),部分患者损伤区可完全消失。结论 发散式体外冲击波治疗轻中度距骨骨软骨损伤可获得良好疗效。     

高强度聚焦超声治疗子宫肌瘤的疗效分析

 目的 探讨高强度聚焦超声(high intensity focused ultrasound, HIFU)治疗子宫肌瘤的临床疗效及安全性。方法 2014-03至2015-06采用HIFU治疗子宫肌瘤患者88例,观察并分析患者术中术后反应、临床症状缓解情况及影像学改变情况。结果 治疗中无神经损伤、膀胱损伤、肠穿孔、皮肤烧伤等严重并发症发生; 35例月经量增多患者治疗后1、3、6个月后月经量减少至原月经量的百分数分别为(71±11)%、(55±10)%、(49±11)%;21例继发性贫血患者治疗前Hb水平为(92±8)g/L、治疗后6个月血红蛋白水平为(121±13) g/L,差异有统计学意义(t=8.71,P<0.05)。24例痛经患者治疗前痛经NPIS评分为(7.8±1.1),治疗后6个月痛经NPIS评分为(2.3±0.8),差异有统计学意义(t=19.81,P<0.05)。治疗后1、3、6个月超声检查显示子宫肌瘤体积缩小率为(33.23±14.03) %、(48.42±14.56) %、(63.76±18.05)%。6个月后超声检查CDFI显示所有患者肌瘤内血流信号明显减少或消失,与治疗前比较,差异有统计学意义(Zc=9.63,P<0.05)。结论 HIFU治疗子宫肌瘤近期疗效显著,能有效减轻临床症状,是治疗子宫肌瘤的安全、有效、无创的新方法。     

扶正消瘤方联合高强度聚焦超声治疗子宫肌瘤的疗效分析

目的：评估扶正消瘤方联合高强度聚焦超声（HIFU）治疗子宫肌瘤的疗效价值。方法：选取98例（113个肌瘤）子宫肌瘤患者,随机分为实验组49例（57个肌瘤）及对照组49例（56个肌瘤）。实验组采用HIFU消融治疗联合扶正消瘤方口服3个月;对照组仅采用HIFU消融治疗。HIFU治疗后6个月行超声造影对2组疗效进行评价。结果：HIFU治疗后6个月,实验组肌瘤体积缩小率明显比对照组高（P<0.05）;实验组治疗显效率（91.23%）,明显高于对照组（64.29%）（P<0.05）。结论：扶正消瘤方联合HIFU治疗子宫肌瘤,结合超声造影技术实时动态评估,临床效果显著。     

高强度聚焦超声消融子宫肌瘤的MRI评价

目的 观察高强度聚焦超声(HIFU)消融治疗子宫肌瘤的客观疗效、不良反应和临床转归情况.方法 2006年12月-2008年3月解放军第307医院参与多中心临床验证的子宫肌瘤确诊患者38例(包括多发肌瘤患者17例),使用HIFU治疗系统一次性消融治疗子宫肌瘤47个,其中肌瘤最大直径11.6cm.观察不良反应并定期随访,随访期间应用增强磁共振(MRI)评价HIFU治疗后子宫肌瘤的消融坏死体积及消融率,测量治疗后子宫和肌瘤体积的变化,判断临床转归规律.结果 治疗后随访37例共46个肌瘤,增强MRI显示所有肌瘤均出现消融坏死区并持续存在,HIFU消融率为65.1%±21.7%.与治疗前相比,治疗后不同时间子宫和肌瘤体积均有显著缩小,1、3、6、12个月时子宫肌瘤的缩小率分别为24.1%±17.3%、39.8%±23.4%、44.6%±24.7%、60.3%±17.2%(F=15.31,P<0.01),呈现出随时间延长逐渐缩小的变化规律.HIFU治疗后的主要并发症为局部疼痛、发热等,均为轻中度,并可在1周内自行缓解.结论 HIFU消融治疗子宫肌瘤安全可行,局部消融效果确切.     

CT引导下经皮穿刺微波消融治疗老年人巨块型肺癌的疗效

 目的 探讨CT引导下经皮穿刺微波消融治疗老年人巨块型肺癌的疗效。方法 选择2013-03至2015-03在CT引导下经皮微波消融治疗26例不能手术切除的巨块型肺癌患者,所有病例诊断均经术前穿刺病理证实,其中鳞癌18例,腺癌7例,腺鳞癌1例。术后即刻、3、6、12个月复查增强CT,评价肿瘤体积缩小及坏死情况,分别于术前与术后1个月采用KPS评分评价患者生存质量,随访时间为12个月。结果 26例32次微波手术均获得成功,其中6例于术后1周行二次微波消融手术。微波消融治疗结束后即刻行CT增强扫描,其中CA 5例(19.2%),PA19例(73.1%),SD 2例(7.7%),总体有效率为92.3%。所有患者瘤体负荷显著减轻,治疗前KPS评分为78.23±11.54,治疗后1个月KPS评分为85.13±10.22(t=-2.282,P＜0.05);消融术前肿瘤最大径为(10.4±1.3)cm,消融术后3、6、12个月肿瘤最大径分别为(7.6±2.4)cm、(6.2±2.8)cm 和(5.7±2.5)cm,与术前比较,差异有统计学意义(F=21.482,P＜0.05)。结论 CT引导下经皮穿刺微波消融治疗老年人巨块型肺癌是一种安全、微创、减瘤效果显著的介入方法,其远期疗效和对患者生存期的影响还有待进一步研究。     

和血明目片联合雷珠单抗治疗湿性年龄相关性黄斑变性的临床效果

 目的 观察和血明目片联合抗血管内皮生长因子(vascular endothelial growth factor, VEGF)药物雷珠单抗治疗湿性年龄相关性黄斑变性(wet age-related macular degeneration, wAMD)的临床效果。方法 选择2016-06至2018-06收治的96例(96只眼)wAMD患者,按照随机数字表法分为治疗组和对照组,每组48例(48只眼)。治疗组给予雷珠单抗球内注射联合和血明目片口服治疗,对照组仅给予雷珠单抗球内注射治疗。两组均连续治疗3个月,治疗结束后随访3个月,观察最佳矫正视力(best corrected visual acuity,BCVA)、黄斑区视网膜中央厚度(central retinal thickness,CRT)、黄斑出血面积、渗出面积及累积损伤面积等情况,随访结束后黄斑水肿复发情况,并进行统计学评价。结果 (1)BCVA:治疗3个月后,两组均比治疗前升高(t=8.320,t=4.689,P＜0.01),且治疗组高于对照组(t=2.509,P＜0.01);随访3个月后,两组均比治疗前高,差异有统计学意义(t=7.909,t=3.808,P＜0.01),且治疗组高于对照组(t=3.164,P＜0.01)。(2)CRT:治疗3个月后,两组均低于治疗前(t=16.864,t=14.175,P＜0.01),但两组间差异无统计学意义(t=1.402);随访3个月后,两组均低于治疗前,差异有统计学意义(t=14.478,P＜0.01),且治疗组低于对照组(t=2.687,P＜0.05)。(3)治疗后3个月,两组眼底出血、渗出及总的累积损伤面积均较治疗前明显缩小(P均＜0.05),且治疗组眼底出血面积(t=2.893,P＜0.05)和累积损伤面积缩小幅度(t=2.164,P＜0.05)较对照组更明显,均有统计学意义。(4)两组复发率比较,差异有统计学意义(χ²=4.937,P＜0.05)。结论 抗VEGF球内注射联合和血明目片治疗wAMD的临床疗效肯定,联合治疗在控制黄斑出血及水肿复发方面有优势。     

碳酸司维拉姆治疗维持性透析患者高磷血症的有效性和安全性

 目的 评价碳酸司维拉姆治疗维持性血液透析(MHD)合并高磷血症的有效性和安全性。方法 选取2017-05至2018-01陆军总医院MHD合并高磷血症患者共81例,随机分为试验组和对照组,两组在常规治疗基础上分别应用碳酸司维拉姆(n＝39)和醋酸钙(n＝42)进行治疗,观察6个月,记录两组患者血磷、血钙、钙磷乘积、甲状旁腺激素(iPTH)及低密度脂蛋白水平,同时记录不良反应。结果 (1)试验组治疗后2、4、6个月血清磷明显降低(P＜0.05),对照组治疗后4、6个月明显降低(P＜0.05)。两组间对比,试验组在治疗2个月时水平低于对照组(P＜0.05)。(2)试验组治疗2、4、6个月时血清钙水平无明显变化,对照组治疗4、6个月时较治疗前有所增加(P＜0.05),试验组在治疗6个月时水平低于对照组(P＜0.05)。(3)试验组在治疗2、4、6个月后钙磷乘积水平明显下降(P＜0.05),对照组在治疗6个月后水平较治疗前下降(P＜0.05),试验组在治疗6个月时水平低于对照组(P＜0.05)。(4)两组治疗后iPTH水平均显著降低(P＜0.05)。(5)试验组低密度脂蛋白在治疗6个月后较治疗前明显降低(P＜0.05),对照组治疗6个月后无明显变化。(6)两组间不良反应发生率无统计学差异。结论 碳酸司维拉姆能安全有效地用于治疗维持性透析患者高磷血症,并且在降低钙磷乘积和低密度脂蛋白方面和醋酸钙相比有一定优势。     

肥胖合并2型糖尿病患者胃旁路手术后相关指标的变化

 目的 探讨肥胖合并2型糖尿病患者腹腔镜胃旁路手术(LRYGB)后相关指标的变化。方法 回顾性分析2011-03至2012-02在原武警总医院普外科接受LRYGB的52例肥胖合并2型糖尿病患者的临床资料,分别在术前、术后3、6、12个月,采用人体成分分析仪检测全身脂肪总量和非脂肪总量变化,通过日本东芝公司80排螺旋CT+美国明维思公司校准体模和定量CT(QCT)分析软件,记录腹部总体脂肪体积(TAFV)、腹部内脏脂肪总体积(TVFV)和腹部皮下脂肪总体积(TSFV)的变化;同时测定相应时间点血清瘦素、脂联素(APN)及糖脂代谢指标,部分指标随访5年。结果 (1)术后12个月糖尿病达标率为86.5%,肥胖症治愈率为67.3%,术后各时间点空腹胰岛素(Fins)和HOMA-IR数值呈逐渐下降趋势,仅在术后12个月和术后5年明显下降,差异有统计学意义(P＜0.05)。与术前相比,在术后12个月三酰甘油(TG)、胆固醇(CH)下降明显,差异均有统计学意义(P＜0.05),术后5年TG略有升高,但与术前差异仍有统计学意义(P＜0.05)。(2)与术前相比,术后6、12个月和2年瘦素下降明显,差异均有统计学意义(P＜0.05);术后APN在术后3个月略有下降,然后呈逐渐升高趋势,在术后12个月和2年APN数值显著升高,差异均有统计学意义(P＜0.05)。(3)术后各时间点体重和BMI均呈下降趋势,术后5年下降明显,与术前比较,差异有统计学意义(P＜0.05)。术后非脂肪总量有下降趋势,但仅在术后5年时变化明显。与术前相比,术后6个月TVFV显著下降,术后12个月TSFV显著下降,术后5年TSFV和TVFV均显著下降,差异有统计学意义(P＜0.05)。结论 LRYGB术后腹部内脏脂肪较皮下脂肪减少更为显著,伴血清瘦素降低和APN增高。     

超声引导下射频消融治疗子宫肌瘤临床价值研究

目的评估超声引导下射频消融治疗子宫肌瘤的临床疗效与安全性。方法对解放军85医院自2012年3月至2013年3月收治的148例子宫肌瘤患者进行超声引导下射频消融治疗。记录患者术前的主要症状。术前及术后3、6、12个月行阴式B超检查,观察肌瘤的位置,测量肌瘤3条径线长度,计算平均肌瘤体积及肌瘤缩小率。在术前及术后12个月采用子宫肌瘤症状及健康相关生活质量问卷(UFS-HRQL)评估子宫肌瘤相关症状及生活质量改善情况。观察术后12个月内术并发症发生情况。结果术前,术后3、6、12个月肌瘤平均体积分别为(23.33±22.80)cm~3、(12.47±11.83)cm~3、(6.88±6.52)cm~3及(4.45±4.26)cm~3;各术后组与术前组肌瘤平均体积比较,差异均有统计学意义(P<0.05)。术后3、6、12个月肌瘤缩小率分别为49.6%、70.3%、80.3%。117例有症状的患者中,术前、术后12个月平均UFS评分分别为(33.51±13.94)分、(5.77±4.50)分;平均QOL评分为分别为(68.09±15.17)分、(90.79±5.52)分;术前、术后UFS评分及QOL评分比较,差异均有统计学意义(P<0.05)。随访12个月,无严重并发症发生。结论 B超引导下射频消融子宫肌瘤对于无生育要求的、肌瘤较小(直径<6.5 cm)、随访条件好的患者,是一种临床价值较高的治疗手段,值得推广应用。     

影响子宫肌瘤栓塞治疗的因素

目的观察子宫动脉栓塞术(UAE)对子宫肌瘤的治疗效果,并分析影响疗效的因素。方法46例症状性子宫肌瘤患者经超选择性插管双侧子宫动脉内注入PVA微粒栓塞治疗,术后6、9个月随访复查,观察临床症状改善,肌瘤体积变化情况,并对临床上治疗效果与多种不同的影响因素进行分析。结果UAE术后临床症状改善,尤其以子宫出血症状改善最为明显,栓塞后6个月肌瘤体积平均缩小45.6%,9个月肌瘤体积平均缩小58.4%。盆腔内血管解剖、内分泌、栓塞技术及肌瘤类型等因素影响子宫肌瘤栓塞后的疗效。结论双侧子宫动脉栓塞治疗子宫肌瘤是一种安全、有效的方法,其疗效与盆腔内血管解剖、内分泌、栓塞技术及肌瘤类型等多种因素有关。     

Magnetic resonance imaging-guided focused ultrasound ablation of uterine fibroids: early clinical experience

PURPOSE: The aim of this study was to assess the feasibility and effectiveness of magnetic resonance (MRI)-guided focused ultrasound (MRIgFUS) ablation for uterine fibroids and to identify the candidates for this treatment. MATERIALS AND METHODS: A total of 48 patients with a symptomatic uterine fibroid underwent MRIgFUS. The percent ablation volume was calculated, and the patients' characteristics and the MR imaging features of the fibroids that might predict the effect of this treatment were assessed. Changes in the symptoms related to the uterine fibroid were assessed at 6 and 12 months. RESULTS: The planned target zone were successfully treated in 32 patients with bulk-related and menstrual symptoms but unsuccessfully treated in the remaining 16 patients. These 16 patients were obese or their uterine fibroid showed heterogeneous high signal intensity on T2-weighted images. The 32 successfully treated patients were followed up for 6 months. At the 6-month follow-up, bulk-related and menstrual symptoms were diminished in 60% and 51% of patients, respectively. Among them, 17 patients were followed up for 12 months, and 9 of them who showed alleviation of bulk-related symptoms at 6 months had further improvement. The mean percent ablation volume of those nine patients was 51%. In 5 (33%) of the 15 patients with alleviation of menstrual symptoms at 6 months, the symptoms became worse at 12 months. There was a significant difference in the mean percent ablation volume between patients with alleviation of menstrual symptoms and those without (54% vs. 37%; P = 0.03). CONCLUSION: MRIgFUS ablation is a safe, effective treatment for nonobese patients with symptomatic fibroids that show low signal intensity on T2-weighted images. Ablation of more than 50% of the fibroid volume may be needed with a short-term follow-up.     

Targeted Vessel Ablation for More Efficient Magnetic Resonance-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids

Purpose

To report the first clinical experience with targeted vessel ablation during magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) treatment of symptomatic uterine fibroids.

Methods

Pretreatment T1-weighted contrast-enhanced magnetic resonance angiography was used to create a detailed map of the uterine arteries and feeding branches to the fibroids. A three-dimensional overlay of the magnetic resonance angiography images was registered on 3D T2-weighted pretreatment imaging data. Treatment was focused primarily on locations where supplying vessels entered the fibroid. Patients were followed 6?months after treatment with a questionnaire to assess symptoms and quality of life (Uterine Fibroid Symptom and Quality of Life) and magnetic resonance imaging to quantify shrinkage of fibroid volumes.

Results

In two patients, three fibroids were treated with targeted vessel ablation during MR-HIFU. The treatments resulted in almost total fibroid devascularization with nonperfused volume to total fibroid volume ratios of 84, 68, and 86%, respectively, of treated fibroids. The predicted ablated volumes during MR-HIFU in patients 1 and 2 were 45, 40, and 82?ml, respectively, while the nonperfused volumes determined immediately after treatment were 195, 92, and 190?ml respectively, which is 4.3 (patient 1) and 2.3 (patient 2) times higher than expected based on the thermal dose distribution. Fibroid-related symptoms reduced after treatment, and quality of life improved. Fibroid volume reduction ranged 31–59% at 6?months after treatment.

Conclusion

Targeted vessel ablation during MR-HIFU allowed nearly complete fibroid ablation in both patients. This technique may enhance the use of MR-HIFU for fibroid treatment in clinical practice.     

参苓白术散对稳定期COPD老年患者血清炎性因子与心理状态的影响

 目的 研究参苓白术散加减联合呼吸训练治疗稳定期慢性阻塞性肺疾病(chronic obstructive pulmonary disease ,COPD)老年患者的疗效及对其血清炎性因子、心理状态及心力衰竭标志物的影响。方法 选取医院2016-01至2017-08收治的96例COPD稳定期老年患者,按随机数字表法分为对照组和治疗组,每组48例;对照组采取常规西药治疗,治疗组在对照组治疗的基础上应用参苓白术散加减联合呼吸训练治疗,治疗1个疗程后评估两组临床疗效,观察治疗前后心理状态、活动能力、心力衰竭标志物、血清炎性因子、6 min步行试验及血气分析指标的变化情况。结果 治疗组总有效率为95.83%,对照组总有效率为83.33%,差异有统计学意义(P＜0.05)。治疗后心理状态、活动能力两组均较治疗前改善(P＜0.05);治疗后两组hs-CRP、BNP、6MWT均较前改善(P＜0.05);治疗后治疗组各项指标均较对照组改善明显(P＜0.05)。治疗后两组PaO₂、SaO₂、PaCO₂均较前改善,但差异无统计学意义;治疗1个疗程后治疗组PaO₂、SaO₂、PaCO₂均优于对照组,差异有统计学意义(P＜0.05)。结论 参苓白术散联合呼吸训练能够提高稳定期COPD老年患者的临床疗效,降低血清炎性因子表达水平,缓解患者焦虑、抑郁的心理症状。     

Feasibility of magnetic resonance imaging-guided high intensity focused ultrasound therapy for ablating uterine fibroids in patients with bowel lies anterior to uterus

Purpose

To prospectively evaluate the feasibility of magnetic resonance (MR) imaging-guided high intensity focused ultrasound (HIFU) therapeutic ablation of uterine fibroids in patients with bowel lies anterior to uterus.

Materials and methods

Twenty-one patients with 23 uterine fibroids underwent MR imaging-guided high intensity focused ultrasound treatment, with a mean age of 39.4 ± 6.9 (20-49) years, with fibroids average measuring 6.0 ± 1.6 (range, 2.9-9.5) cm in diameter. After being compressed with a degassed water balloon on abdominal wall, MR imaging-guided high intensity focused ultrasound treatment was performed under conscious sedation by using fentanyl and midazolam. This procedure was performed by a Haifu^® JM focused ultrasound tumour therapeutic system (JM2.5C, Chongqing Haifu Technology Co., Ltd., China), in combination with a 1.5-Tesla MRI system (Symphony, Siemens, Germany), which provides real-time guidance and control. Contrast-enhanced MR imaging was performed to evaluate the efficacy of thermal ablation immediately and 3 months after HIFU treatment. The treatment time and adverse events were recorded.

Results

The mean fibroid volume was 97.0 ± 78.3 (range, 12.7-318.3) cm³. According to the treatment plan, an average 75.0 ± 11.4% (range, 37.8-92.4%) of the fibroid volume was treated. The mean fibroid volume immediately after HIFU was 109.7 ± 93.1 (range, 11.9-389.6) cm³, slightly enlarged because of edema. The average non-perfused volume was 83.3 ± 71.7 (range, 7.7-282.9) cm³, the average fractional ablation, which was defined as non-perfused volume divided by the fibroid volume immediately after HIFU treatment, was 76.9 ± 18.7% (range, 21.0-97.0%). There were no statistically significant differences between the treatment volume and the non-perfused volume. Follow-up magnetic resonance imaging (MRI) at 3 months obtained in 12 patients, the fibroid volume decreased by 31.4 ± 29.3% (range, −1.9 to 60.0%) in average, with paired t-test showing a statistically significant reduction (P = 0.002). The mean treatment time for ablating the average 83.3 ± 71.7 (range, 7.7-282.9) cm³ of fibroid volume was 2.5 ± 1.4 h (range, 27-390 min) in this study, which was relatively short and acceptable to patient and therapist. Four patients experienced mild skin burn (two with skin redness, two with blisters), the skin burn subsided within ∼2 days. No other adverse events were observed.

Conclusions

After the bowel was compressed with a degassed water balloon, MR imaging-guided high intensity focused ultrasound treatment is safe and feasible in ablating uterine fibroids in patients with bowel lies anterior to uterus.     

Uterine artery embolization of symptomatic uterine fibroida . Initial success and short-term results

PURPOSE: To evaluate reduction in fibroid volume, the effect on clinical symptoms, adverse events and complications after percutaneous uterine artery embolization (UAE) as primary invasive treatment for symptomatic uterine fibroids. MATERIAL AND METHODS: Sixty-two patients entered the study. Indications for treatment were fibroid-induced menorrhagia, bulk symptoms, pain, and/or large fibroid size. The first 50 patients were evaluated by clinical examination and ultrasonography with measurement of fibroid volume before treament and 1, 6 and 12 months after UAE. The remaining 12 patients were followed 3 and 12 months after treatment. Embolization with microparticles was performed percutaneously in local analgesia by selective catheterization of both uterine arteries. RESULTS: A primary technical success with bilateral UAE was achieved in 60/62 (97%) of the patients. They were treated for postprocedural pain lasting up to 24 h. In 30 of the 62 patients with 6 months follow-up, the mean fibroid volume was reduced 68% 6 months after treatment. Twenty-nine (96%) of the patients experienced reduced bleeding, 21 (70%) reduced pain, and 18 (61%) reduced bulk symptoms at follow-up. CONCLUSION: UAE is a method with a high technical success rate. The treatment has good effect on fibroid volume reduction and clinical symptoms. Severe post-procedural pain occurs generally in successful bilateral embolizations, but complications and adverse events are otherwise few and minor. UAE represents a promising new method for treating uterine fibroid-related symptoms.